Inaugural Southern California Genitourinary Cancer Research Forum

Key Updates in Bladder Cancer

Alexandra Drakaki, MD, PhD

Associate Professor of Medicine, Hematology/Oncology and Urology

Medical Director of the Genitourinary Oncology Program

Leader of the Genitourinary Research Program

University of California, Los Angeles



Bladder Cancer Can we finally make a difference ??? From NeoAdjuvant to Adjuvant to Metastatic, and there is still a **Chance of Cure!!!**



• Consultant for AstraZeneca, Eli Lilly, EMD Serono, Exelixis, Genentech, Merck, and Seagen.

This presentation and/or comments will be free of any bias toward or promotion of the above referenced companies or their product(s) and/or other business interests.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.

This presentation has been peer-reviewed and no conflicts were noted.

The off-label/investigational use of Durvalumab, Tremelimumab, Tiragolumab, Atezolizumab, and Enfortumab Vedotin will be addressed.

Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

STATE LAW:

The California legislature has passed <u>Assembly Bill (AB) 1195</u>, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed <u>AB 241</u>, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

EXEMPTION:

Business and Professions Code 2190.1 exempts activities which are dedicated solely to research or other issues that do not contain a direct patient care component.


This presentation is dedicated solely to research or other issues that do not contain a direct patient care component.



- NEOADJUVANT: Current SOC and Ongoing Needs / Studies
- ADJUVANT: Making science to make a difference!
- METASTATIC: Finally a step forward

Basic Principle in Urothelial Cancer <u>Treat based on Cisplatin Eligibility</u> For Neoadjuvant-Adjuvant-1st Line Metastatic

- 1. Creatinine Clearance > 60 (Adjusting to Cr Cl 40-60)
- 2. Neuropathy grade <2 (Subjective grade 1 vs 2)
- 3. Ototoxicity grade <2 (Subjective need vs use hearing aids)
- 4. NYHA class <3
- 5. ECOG 0-1






Current SOC In Cisplatin Eligible


MULTICENTER RANDOMIZED PHASE III TRIAL OF DOSE DENSE MVAC OR GC IN PERIOPERATIVE CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER GETUG/AFU VESPER PH III

ASCO 2023

GC: Gemcitabine Cisplatin

MVAC: Methotrexate Vinblastine Anthracycline Cisplatin





GETUG/AFU VESPER Ph III

500 patients randomized to ddMVAC * 6cy vs GC * 4cy

5yr OS 64% in dd MVAC vs 56% in GC


5yr DFS 72% in dd MVAC vs 59% in GC NEOADJUVANT

1 ADC binds and intereleased payload e

4 Activated T cells and NK cells target and kill tumo

CISPLATIN ELIGIBLE TRIALS

KEYNOTE-B15: A Phase III study of Gemcitabine+Cisplatin vs Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (PI: Chamie-urology)




What is the SOC in Cisplatin Ineligible?


- Bladder Sparing: Chemo Radiation
- Surgical Candidates: Radical Cystectomy & LN Dissection \rightarrow Adjuvant Tx

<u>Neoadjuvant therapy is the SOC in MIBC</u> If that holds true for CISPLATIN ELIGIBLE, is probably true for CISPLATIN INELIGIBLE IF we can give <u>Effective Drugs Safely</u>


NEOADJUVANT

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma





Pathologic Responses post cystectomy



1.0. (1.1.1.) 18 30 24 **Relapse Free Survival**

medicine

LETTERS


https://doi.org/10.1038/s41591-020-1086-y

Gao et al 2020

NEOADJUVANT

EV-103 Cohort H: Neoadjuvant Enfortumab Vedotin in patients Cisplatin Ineligible MIBC

J Clin Oncol. 40, 2022 (suppl 6; abstr 435)



Pathological Response	Central Pathology Results (N=22) n (%) [95% Confidence Interval]		
Pathological Complete Response Rate	8 (36.4%)		
(defined as absence of any viable tumor tissue: ypT0 and N0)	[17.2–59.3]		
Pathological Downstaging Rate	11 (50.0%)		
(defined as presence of ypT0, ypTis, ypTa, ypT1, and N0)	[28.2–71.8]		

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin Ineligible Untreated Advanced Bladder Cancer

100 100 90 90 80 80 70 70 PFS (%) 60 PFS (%) 60 50 50 40 40 30 30 Median 20 20 N Events (months) 95% CI N Events (months) 95% C 10 73 39 8.0 (6.05 10.35 10 EV + Pembro EV Monotherapy (8.31, -(N = 76)(N = 73)5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 0 1 2 3 4 5 6 7 8 9 1011 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Confirmed ORR, No. (%) 49 (64.5) 33 (45.2) Time (months) Time (months) No. at risk: (95% CI) (52.7, 75.1) (33.5, 57.3)Best overall response 100 100 CR 8 (10.5) 3 (4.1) 90 90 ┈╊╄╫┉╪╬╕╋┑╷╪╋╪╋┈╬╫┓_{┿╇╋╋} 80 80 PR 41 (53.9) 30 (41.1) 70 70 (%) SO 60 50 40 (%) SO 60 Stable disease 17 (22.4) 25 (34.2) 50 40 PD 6 (7.9) 7 (9.6) 30 30 20 Mediar 10 (19.09)20 95% C 10 21.7 (15.21. -26 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 0 1 Time (months) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Time (months) EV + Pembro **EV Monotherapy** (N = 76)(N = 73)mPFS, months mPFS, months 8.0

95% CI

95% CI

mOS, months

(6.05, 10.35)

21.7

(15.21, -)

95% CI

95% CI

mOS, months

(8.31, -)

22.3


(19.09, -)


	Journal	of	Clinical	С	nco	logy®
An American Society of Clinical Oncology Journal						

O'Donnell et al, J Clin Oncol 2023

Response rates for Durvalumab vs Durvalumab/Tremilimumab vs Chemo in front line Urothelial Cancer (DANUBE trial)

Cisplatin-eligible population





BUILDING UPON PAST KNOWLEDGE

- ✓ We know Durvalumab-Tremelimumab combo is Safe & Effective in Cisplatin Ineligible
- ✓ EV 103 coh H confirms Enfortumab Vedotin is also safe and effective in this population
- ✓ Durvalumab Adds to Tremelimumab
- \checkmark Enfortumab Vedotin adds to PD-1 Therapy


Let's Study a Triple Combination of

<u>Durvalumab/Tremelimumab/Enfortumab_Vedotin</u> in the Neoadjuvant setting



NEOADJUVANT

Phase 3 Study of Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) or D + EV In Neoadjuvant Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (VOLGA)



Primary Endpoints

- * Pathologic complete response
- * Event-free survival (EFS)

Secondary Endpoints

- * OS, DSS, QOL
- * Pathologic downstaging to <pT2N0M0
- * Safety / Tolerability




ADJUVANT *CURRENT* SOC


JOURNAL OF CLINICAL ONCOLOGY Clinical Trial Updates

Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial

Britle et al, JCO 2024



5-yr DFS **62%** Chemo vs **45%** Surveillance HR = 0.55 (95% CI, 0.38 to 0.80, P = .001)




5-yr OS **66%** Chemo vs **57%** Surveillance HR = 0.68 (95% Cl, 0.46 to 1.00, P 5 .049)

ADJUVANT CURRENT SOC

The NEW ENGLAND JOURNAL of MEDICINE


Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Bajorin et al, June 3, 2021



GU ASCO 2023


AMBASSADOR: Phase 3 Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation



PRESENTED BY: Andrea B. Apolo, MD

AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation

DISEASE FREE SURVIVAL




Median follow-up (range) 22.3 months (0.03-48.9)

ASCO[·]Genitourinary</sup> Cancers Symposium


PRESENTED BY: Andrea B. Apolo, MD

AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation

DISEASE FREE SURVIVAL PER PD-L1 STATUS




AMBASSADOR: Adjuvant Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation




ASCO Genitourinary Cancers Symposium

ADJUVANT


ADJUVANT CLINICAL TRIAL Lessons from the past





Treating Metastatic Bladder Cancer a 10 year journey


The importance of small steps





ORIGINAL ARTICLE

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma






2 Cell death and exposure o



EV-302 A Phase III study of Enfortumab Vedotin & Pembrolizumab vs Gemcitabine + Cisplatin / Carboplatin






EV-302 A Phase III study of Enfortumab Vedotin & Pembrolizumab vs Gemcitabine + Cisplatin / Carboplatin

Confirmed Overall Response per BICR


Significant improvement in objective response rate was observed with EV+P



	EV+P (N=437)	Chemotherapy (N=441)	
Confirmed ORR, n (%) (95% Cl)	296 (67.7) (63.1-72.1)	196 (44.4) (39.7-49.2)	
2-sided P value	< 0.00001		
Best overall response ^a , n (%)			
Complete response	127 (29.1)	55 (12.5)	
Partial response	169 (38.7)	141 (32.0)	
Stable disease	82 (18.8)	149 (33.8)	
Progressive disease	38 (8.7)	60 (13.6)	
Not evaluable/No assessment ^b	21 (4.8)	36 (8.2)	

EV-302 A Phase III study of Enfortumab Vedotin & Pembrolizumab vs Gemcitabine + Cisplatin / Carboplatin

Overall Survival



Risk of death was reduced by 53% in patients who received EV+P

Data cutoff: 08 Aug 2023



Powles et al.

mOS, median overall survival; NR, not reached *Calculated using stratified Cox proportional hazards model. A hazard ratio <1 favors the EV+P arm

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

Life is not about how fast you run or how high you climb. but how well you Bounce.






October 18, 2023

25 years of Herceptin: A groundbreaking advancement in breast cancer treatment

This year marks the 25th anniversary of the FDA approval of the first gene-based drug for cancer, developed by UCLA's Dr. Dennis Slamon





HER-2 IN CANCER


Tumour types						
HER2	HER2	HER2				
amplification (%)	overexpression (%)	mutation (%)				

Phase 2 Study Evaluating the Efficacy & Safety of Disitamab Vedotin in HER-2 expressing Urothelial Ca

Koshkin V, Powles T, Iyer G, Loriot Y, Drakaki A, Duran I, De Santis M, Retz M, Jain R, Chan S, Ichimaru M, Galsky M


Phase 2 Study Evaluating efficacy and safety of Disitimab Vedotin with or without Pembrolizumab in patients with Her2 Urothelial Cancer Matsubara N, Powles T, Rosenberg J, Koshkin V, Brown J, Aragon-Ching J, Drakaki A, O'Donnell P, Yu E, Campbella M, Krieger L, Chan S, Sokolowski K, Galsky M. Japan Society of Clinical Oncology

- $\checkmark\,$ HER-2 overexpression correlates with poor outcome in UC
- ✓ No HER-2 directed tx approved for UC in USA
- ✓ Phase1B/II DV in HER2 expressing UC : ORR of 51 %
- ✓ DV has breakthrough designation in China for gastric and UC
- $\checkmark\,$ DV & Pembro in HER2 untreated UC




congress

Study Design



What's Next

Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; Trial in Progress).




What's Next


Enfortumab Vedotin Antibody-Drug Conjugate **Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models**

		H-Score *			
Cancer type	Overall positive (%)	Strong	Moderate	Low	Negative
Bladder (N = 524)	83	162 (31)	154 (29)	118 (23)	90 (17)
Breast (N = 654)	78	174 (27)	168 (26)	170 (26)	142 (22)
Pancreatic (N = 164)	71	21 (13)	39 (24)	56 (34)	48 (29)
Lung (N = 618)	55	46 (7)	121 (20)	173 (28)	278 (45)
Ovarian (N = 118)	57	0	21 (18)	46 (39)	51 (43)
Head & Neck (N = 135)	59	3 (2)	22 (16)	54 (40)	56 (41)
Esophageal (N = 181)	55	7 (4)	37 (20)	55 (30)	82 (45)
Total (N = 2,394)	69	413 (17)	562 (24)	672 (28)	747 (31)
* H-Score based on in	tensity of staining:	200-300	100-199	15-99	0-14


Challita-Eid et al, Cancer Res 2016



Breast, H-score =110



Bladder, H-score= 250




Pancreatic, H-score=300

Lung, H-score= 250



ClinicalTrials.gov NCT06036121

- Part A Dose Escalation in patients with histologically confirmed select solid tumors
 - UC, HNSCC, breast, cervical, ovarian, NSCLC, pancreatic
- Part B Dose Expansion in three disease-specific cohorts



The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

*Activating mutations common (~86%) in low grade, early stage bladder tumors *TCGA: ~12% with mutations in MIBC

*FGFR 3 mutations/fusions(~21%) in advanced UC, UTUC - high-grade, invasive *ERDAFITINIB: oral, potent pan FGFR inhibitor

- 99 pts / 40% RR






LOXO-FG3-22001 : AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS

STUDY DESIGN


PHASE 1A: DOSE ESCALATION

Cohort A: All Solid Tumors

LOXO-435 monotherapy in patients with advanced solid tumors with an alteration in *FGFR3* or its ligands deemed as a clinically or potentially clinically relevant alteration



GU ONCOLOGY PROGRAM: Meet the Team



John Shen, MD



Nicholaos Palaskas, MD, PhD

Alexandra Drakaki, MD, PhD



Lidia Lopez, NP



Adam Singer, MD, PhD

Coordinators Satellites

Glaucia Vazquez

Margarita Torres

Jacob Medina

Maria Mejia

Mashal Chhotani

Yuritzi Palma



John Lee, MD, PhD

Research Assistants Parker Sundeen

Data Managers Jaelyn Abad Sam Xiong Lucia Verdugo

Regulatory

Soheila Abbassi Michelle Poblete Sarah Rosales

Coordinators(SM/WW)

Whitney Vuong Sandy Hernandez Rosa Vazquez Chris Hannigan Cynthia Avina Annabel Liu



Sometimes there is only one chance for <u>CURE</u>

Let's Make a Change Together



Thank you